综述 |
|
|
|
|
埃博拉病毒疫苗rVSV-ZEBOV的研究进展 |
张杨玲,汪园,张革() |
中山大学药学院 广州 510006 |
|
Advances in Research on Ebola Virus Vaccine: rVSV-ZEBOV |
Yang-ling ZHANG,Yuan WANG,Ge ZHANG() |
School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China |
[1] |
Reynolds P, Marzi A . Ebola and Marburg virus vaccines. Virus Genes, 2017, 53(4): 501-515.
doi: 10.1007/s11262-017-1455-x
pmid: 28447193
|
[2] |
许黎黎, 张连峰 . 埃博拉出血热及埃博拉病毒的研究进展. 中国比较医学杂志, 2011, 21(1): 70-74.
doi: 10.3969/j.issn.1671-7856.2011.01.016
|
|
Xu L L, Zhang L F . Progress on Ebola hemorrhagic fever and Ebola viruses. Chinese Journal of Comparative Medicine, 2011, 21(1): 70-74.
doi: 10.3969/j.issn.1671-7856.2011.01.016
|
[3] |
Wang Y, Li J, Hu Y , et al. Ebola vaccines in clinical trial: The promising candidates. Human Vaccines & Immunotherapeutics, 2017, 13(1): 153-168.
doi: 10.1080/21645515.2016.1225637
pmid: 27764560
|
[4] |
Martins K A, Jahrling P B, Bavari S , et al. Ebola virus disease candidate vaccines under evaluation in clinical trials. Expert Review of Vaccines, 2016, 15(9): 1101-1112.
doi: 10.1080/14760584.2016.1187566
pmid: 27160784
|
[5] |
Rao M, Bray M, Alving C R , et al. Induction of immune responses in mice and monkeys to Ebola Virus after immunization with liposome-encapsulated irradiated Ebola virus: Protection in Mice Requires CD4 + T Cells . Journal of Virology, 2002, 76(18): 9176.
doi: 10.1128/JVI.76.18.9176-9185.2002
pmid: 136452
|
[6] |
Feldmann H, Jones S M , Daddario-DiCaprio K M, et al. Effective post-exposure treatment of Ebola infection. PLoS Pathogens, 2007, 3(1): e2.
doi: 10.1371/journal.ppat.0030002
pmid: 17238284
|
[7] |
Jacobs M, Aarons E, Bhagani S , et al. Post-exposure prophylaxis against Ebola virus disease with experimental antiviral agents: a case-series of health-care workers. The Lancet Infectious Diseases, 2015, 15(11): 1300-1304.
doi: 10.1016/S1473-3099(15)00228-5
pmid: 26321189
|
[8] |
WHO. Table of vaccine clinical trials.[ 2017-10-14]. Table of vaccine clinical trials. [2017-10-14].
|
[9] |
Jones S M, Feldmann H, Str?her U , et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nature Medicine, 2005, 11(7): 786-790.
doi: 10.1038/nm1258
pmid: 15937495
|
[10] |
Qiu X, Fernando L, Alimonti J B , et al. Mucosal immunization of cynomolgus macaques with the VSVDeltaG/ZEBOVGP vaccine stimulates strong Ebola GP-specific immune responses. PLoS One, 2009, 4(5): e5547.
doi: 10.1371/journal.pone.0005547
|
[11] |
Regules J A, Beigel J H, Paolino K M , et al. A recombinant vesicular stomatitis virus ebola vaccine. New England Journal of Medicine, 2017, 376(4): 330-341.
doi: 10.1056/NEJMoa1414216
pmid: 25830322
|
[12] |
Agnandji S T, Huttner A, Zinser M E , et al. Phase 1 Trials of rVSV Ebola vaccine in Africa and Europe- Preliminary Report. New England Journal of Medicine, 2016, 374(17): 1647-1660.
doi: 10.1056/NEJMoa1502924
|
[13] |
Medaglini D, Harandi A M, Ottenhoff T H , et al. Ebola vaccine R&D: Filling the knowledge gaps. Science Translational Medicine. 2015, 7(317): 317ps24-317ps24.
|
[14] |
Henao-Restrepo A M, Longini I M, Egger M , et al. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial. Lancet, 2015, 386(9996): 857-866.
doi: 10.1016/S0140-6736(15)61117-5
pmid: 26248676
|
[15] |
Henao-Restrepo A M, Camacho A, Longini I M , et al. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola ?a Suffit!). Lancet, 2016, 389(10068): 505-518.
|
[16] |
Widdowson M A, Schrag S J, Carter R J , et al. Implementing an Ebola vaccine study-sierra leone. Mmwr Supplements, 2016, 65(3): 98.
doi: 10.15585/mmwr.su6503a14
pmid: 27387395
|
[17] |
Rivera A, Messaoudi I . Molecular mechanisms of Ebola pathogenesis. Journal of Leukocyte Biology, 2016, 100(5): 889-904.
doi: 10.1189/jlb.4RI0316-099RR
pmid: 27587404
|
[18] |
Geisbert T W, Feldmann H . Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections. The Journal of Infectious Diseases, 2011, 204(Suppl-3): S1075-1081.
doi: 10.1093/infdis/jir349
pmid: 3218670
|
[19] |
Lawson N D, Stillman E A, Whitt M A , et al. Recombinant vesicular stomatitis viruses from DNA. Proceedings of the National Academy of Sciences of the United States of America, 1995, 92(10): 4477-4481.
doi: 10.1073/pnas.92.10.4477
pmid: 7753828
|
[20] |
Schnell M J, Buonocore L, Whitt M A , et al. The minimal conserved transcription stop-start signal promotes stable expression of a foreign gene in vesicular stomatitis virus. Journal of Virology, 1996, 70(4): 2318-2323.
doi: 10.3109/13550289609146547
pmid: 8642658
|
[21] |
Garbutt M, Liebscher R, Wahl-Jensen V , et al. Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses. Journal of Virology, 2004, 78(10): 5458-5465.
doi: 10.1128/JVI.78.10.5458-5465.2004
pmid: 15113924
|
[22] |
Marzi A, Feldmann H, Geisbert T W , et al. Vesicular stomatitis virus-based vaccines for prophylaxis and treatment of filovirus infections. Journal of Bioterrorism & Biodefense, 2011, S1(4): 2157-2526-S1-004.
doi: 10.4172/2157-2526.S1-004
pmid: 3265573
|
[23] |
Shuchman M . Ebola vaccine trial in west Africa faces criticism. Lancet, 2015, 385(9981): 1933-1934.
doi: 10.1016/S0140-6736(15)60938-2
pmid: 25979835
|
[24] |
Mire C E, Matassov D, Geisbert J B , et al. Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus. Nature, 2015, 520(7549): 688-691.
doi: 10.1038/nature14428
pmid: 25853476
|
[25] |
Clarke D K, Nasar F, Lee M , et al. Synergistic attenuation of vesicular stomatitis virus by combination of specific G gene truncations and N gene translocations. Journal of Virology, 2007, 81(4): 2056-2064.
doi: 10.1128/JVI.01911-06
|
[26] |
Marzi A, Engelmann F, Feldmann F , et al. Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110(5): 1893-1898.
doi: 10.1073/pnas.1209591110
pmid: 23319647
|
[27] |
Menicucci A R, Sureshchandra S, Marzi A , et al. Transcriptomic analysis reveals a previously unknown role for CD8 +T-cells in rVSV-EBOV mediated protection . Scientific Reports, 2017, 7(1): 919.
doi: 10.1038/s41598-017-01032-8
pmid: 5430516
|
[28] |
Farooq F, Beck K, Paolino K M , et al. Circulating follicular T helper cells and cytokine profle in humans following vaccination with the rVSV-ZEBOV Ebola vaccine. Scientific Reports, 2016, 6: 27944.
doi: 10.1038/srep27944
pmid: 4914957
|
[29] |
Dahlke C, Kasonta R, Lunemann S , et al. Dose-dependent T-cell dynamics and cytokine cascade following rVSV-ZEBOV immunization. Ebiomedicine, 2017, 19: 107-118.
doi: 10.1016/j.ebiom.2017.03.045
pmid: 28434944
|
[30] |
杨利敏, 李晶, 高福 , 等. 埃博拉病毒疫苗研究进展. 生物工程学报, 2015, 31(1): 1-23.
doi: 10.3760/cma.j.issn.1673-4211.2015.02.005
|
|
Yang L M, Li J, Gao F , et al. Overview of Ebola virus vaccine. Chinese Journal of Biotechnology, 2015, 31(1): 1-23.
doi: 10.3760/cma.j.issn.1673-4211.2015.02.005
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|